111,244 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 111,244 shares of the medical equipment provider’s stock, valued at approximately $11,773,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet in the fourth quarter valued at about $25,000. Dunhill Financial LLC lifted its position in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the period. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $35,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $39,000. Finally, OFI Invest Asset Management bought a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $40,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Stock Up 0.5 %

Shares of Zimmer Biomet stock opened at $111.31 on Tuesday. The firm has a market cap of $22.16 billion, a PE ratio of 25.01, a P/E/G ratio of 1.95 and a beta of 1.04. The business’s 50 day simple moving average is $106.86 and its 200 day simple moving average is $106.86. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the firm earned $2.20 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. Zimmer Biomet’s dividend payout ratio is 21.57%.

Analyst Ratings Changes

A number of equities analysts have issued reports on ZBH shares. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays dropped their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.